Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

NCT02832999 · Completed

Last updated 2026-05-28

This clinical trial compares how two diabetes medications, liraglutide and vildagliptin, affect insulin sensitivity in adults with type 2 diabetes over a short period.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 14 people

Who can join Ages 21–70 · all sexes

Timeline Started 2016-01 · est. completion 2016-12

Where 1 site · Cameroon

What this study is testing ClinicalTrials.gov NCT02832999 ↗

Description as written by the study sponsor.

This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes mellitus patients on oral glucose lowering agents, and naive to incretinomimetic. Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day changes in insulin secretion and insulin sensitivity.

Treatments tested

sub cutaneous liraglutide also known as Victoza Drug

Liraglutide 1.2mg/day
Oral Vildagliptin also known as Galvus Drug

Vildagliptin 50mg/day

Main thing measured	Insulin sentivity
Sponsor	Yaounde Central Hospital
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02832999 ↗